Zacks Research Weighs in on Longeveron FY2028 Earnings

Longeveron Inc. (NASDAQ:LGVN) – Zacks Research issued their FY2028 earnings per share estimates for Longeveron in a research note issued on Tuesday, February 17th. Zacks Research analyst B. Sorensen expects that the company will post earnings per share of ($1.65) for the year. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Longeveron in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $6.50.

Longeveron Price Performance

Longeveron stock opened at $0.58 on Thursday. Longeveron has a 12 month low of $0.49 and a 12 month high of $1.92. The company has a fifty day moving average price of $0.56 and a two-hundred day moving average price of $0.70. The company has a market cap of $12.27 million, a PE ratio of -0.54 and a beta of 0.21.

Institutional Trading of Longeveron

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd bought a new stake in shares of Longeveron Inc. (NASDAQ:LGVN) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.